Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 7 | 2026 | 147 | 1.330 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2026 | 13 | 0.480 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2015 | 9 | 0.460 |
Why?
|
| Anilides | 1 | 2015 | 24 | 0.460 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2015 | 15 | 0.460 |
Why?
|
| Surgery, Plastic | 2 | 2012 | 19 | 0.460 |
Why?
|
| Pyridines | 1 | 2015 | 108 | 0.430 |
Why?
|
| Internship and Residency | 2 | 2020 | 250 | 0.430 |
Why?
|
| Earthquakes | 1 | 2012 | 5 | 0.380 |
Why?
|
| Disasters | 1 | 2012 | 16 | 0.380 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 80 | 0.340 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 686 | 0.310 |
Why?
|
| Reconstructive Surgical Procedures | 3 | 2020 | 72 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 347 | 0.260 |
Why?
|
| Sigmodontinae | 1 | 2006 | 1 | 0.250 |
Why?
|
| Industrial Waste | 1 | 2006 | 7 | 0.250 |
Why?
|
| Phenylurea Compounds | 1 | 2026 | 17 | 0.240 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2025 | 19 | 0.240 |
Why?
|
| Quinolines | 1 | 2026 | 35 | 0.240 |
Why?
|
| Melanoma | 2 | 2017 | 140 | 0.240 |
Why?
|
| DNA Damage | 1 | 2006 | 152 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2026 | 151 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 433 | 0.180 |
Why?
|
| Aged | 6 | 2026 | 5598 | 0.180 |
Why?
|
| Middle Aged | 7 | 2026 | 7414 | 0.170 |
Why?
|
| Buttocks | 1 | 2020 | 7 | 0.170 |
Why?
|
| Patient Positioning | 1 | 2020 | 23 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2025 | 2635 | 0.160 |
Why?
|
| Gracilis Muscle | 1 | 2020 | 1 | 0.160 |
Why?
|
| Surgical Wound | 1 | 2020 | 2 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 33 | 0.160 |
Why?
|
| Myocutaneous Flap | 1 | 2020 | 3 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2020 | 46 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.150 |
Why?
|
| Students, Medical | 1 | 2020 | 102 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 199 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1032 | 0.140 |
Why?
|
| Humans | 12 | 2026 | 28851 | 0.140 |
Why?
|
| Male | 7 | 2026 | 13921 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 481 | 0.140 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 3 | 0.130 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 46 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 39 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 639 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 93 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 123 | 0.120 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 2 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 35 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 118 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 336 | 0.110 |
Why?
|
| Skin | 1 | 2015 | 152 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2026 | 2065 | 0.110 |
Why?
|
| Female | 7 | 2026 | 15624 | 0.100 |
Why?
|
| Haiti | 1 | 2012 | 3 | 0.100 |
Why?
|
| International Cooperation | 1 | 2012 | 20 | 0.100 |
Why?
|
| Florida | 1 | 2012 | 55 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2017 | 2426 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 116 | 0.090 |
Why?
|
| Margins of Excision | 2 | 2023 | 12 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 191 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 190 | 0.070 |
Why?
|
| Mining | 1 | 2006 | 3 | 0.060 |
Why?
|
| Lead | 1 | 2006 | 9 | 0.060 |
Why?
|
| G1 Phase | 1 | 2006 | 17 | 0.060 |
Why?
|
| Cadmium | 1 | 2006 | 16 | 0.060 |
Why?
|
| Coal | 1 | 2006 | 11 | 0.060 |
Why?
|
| Soil Pollutants | 1 | 2006 | 17 | 0.060 |
Why?
|
| Spleen | 1 | 2006 | 113 | 0.060 |
Why?
|
| Zinc | 1 | 2006 | 63 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2006 | 292 | 0.060 |
Why?
|
| Survival Rate | 1 | 2025 | 432 | 0.050 |
Why?
|
| Prognosis | 1 | 2025 | 811 | 0.050 |
Why?
|
| Prone Position | 1 | 2020 | 5 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2020 | 11 | 0.040 |
Why?
|
| Perineum | 1 | 2020 | 14 | 0.040 |
Why?
|
| Pelvis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 222 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2020 | 1280 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 67 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 190 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 8024 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 997 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 98 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 164 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2833 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 10684 | 0.020 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2011 | 2 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 10 | 0.020 |
Why?
|
| Marijuana Abuse | 1 | 2011 | 16 | 0.020 |
Why?
|
| Amphetamines | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 17 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 118 | 0.020 |
Why?
|